1867 results about "Lactose" patented technology

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

The invention discloses construction and application of an engineering bacterium for co-expressing D-mannitol dehydrogenase and D-glucose dehydrogenase, and belongs to the technical field of genetic engineering. The technical problem to be solved by the invention is how to co-express D-mannitol dehydrogenase and D-glucose dehydrogenase through a biosynthetic pathway. In order to solve the technical problem, the invention provides recombinant escherichia coli. The recombinant escherichia coli is characterized by containing a D-mannitol dehydrogenase gene, a D-glucose dehydrogenase gene, a glucokinase gene, an acetyl coenzyme A synthetase gene, a D-lactose transporter gene, a D-glucose PTS permease-free gene and a pyruvate oxidase-free gene. And no regulator gene of galactose operon is contained. The invention establishes a preparation method for co-producing D-mannitol and sodium gluconate, which has guiding significance for the production of D-mannitol and sodium gluconate.

Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of:a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; anda pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15.Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

The invention relates to application of breast milk oligosaccharides to improvement of intestinal flora of mothers and infants, in particular to application of 2 '-fucosyllactose to preparation of food which is taken by a mother and contributes to regulation of intestinal flora of the mother and offspring thereof, and the mother is in a gestation period and / or a lactation period. The invention is provided through a large amount of research; when a mother supplements a certain amount of 2 '-fucosyllactose in a gestation period and / or a lactation period, the abundance of beneficial bacteria in intestinal tracts of the mother can be remarkably improved, the content of harmful bacteria is reduced, meanwhile, the abundance of beneficial bacteria in intestinal tracts of filial generations of the mother is remarkably improved, and the content of harmful bacteria is reduced; particularly, the abundance of some beneficial bacteria which cannot be directly eaten in the intestinal tracts of the mother and the offspring can be adjusted.

The invention relates to the technical field of freeze-dried preparations, and provides exosome freeze-dried powder as well as a preparation method and application thereof. The exosome freeze-drying preparation is prepared by mixing an exosome solution and a freeze-drying protection solution and then freeze-drying the mixture, the concentration of the exosome solution in the mixed solution is 0.1-10% V / V, and the freeze-drying protection solution comprises 0.4-4% W / V of saccharides and 0.25-4% W / V of alcohols; the saccharide is trehalose, cane sugar or lactose; the alcohol is mannitol, sorbitol or a combination of mannitol and polyethylene glycol; and the solvent is sterilized water for injection or a PBS buffer solution. The exosome freeze-dried powder is stable in activity, small in irritation, good in safety and good in fibroblast proliferation promoting capacity, when the exosome freeze-dried powder is applied to supporting essence or masks in the medical beauty industry, the exosome activity of the exosome freeze-dried powder is still kept stable, and the application prospect is good.

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.

The invention relates to a polymeric composite comprising poly(ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), waterborne polyurethane (WPU) and a sugar alcohol, wherein the sugar alcohol is selected from the group consisting of glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, or a combination thereof, and wherein the sugar alcohol is 20 wt % to 50 wt % of the polymer composite; an electrical device comprising such composite. The present invention also relates to methods of fabricating and its uses thereof. In particular, the present invention relates to intrinsically conductive polymer composites suitable for use in efficient dry / wet epidermal biopotential monitoring. The polymer composites are advantageously self-adhesive and stretchable, and can be used as dry electrodes.

The invention belongs to the technical field of medicines, and provides a cassia twig granular preparation as well as a preparation method and a product thereof. The cassia twig granule preparation is prepared from the following components in parts by weight: 35 to 50 parts of cassia twig granule extract dry paste and 50 to 105 parts of auxiliary materials, the auxiliary materials comprise lactose, beta-cyclodextrin and derivatives thereof, and citric acid. According to the invention, beta-cyclodextrin and derivatives thereof are used for replacing dextrin as an auxiliary material in the cassia twig granules, so that the interference problem of dextrin in drug detection is avoided, the formability, solubility and hygroscopicity of the cassia twig granule preparation are ensured, the stability of the preparation is improved, and the comprehensive performance is excellent.

The invention relates to the technical field of biology, in particular to a beta-1, 4-galactosyl transferase mutant and a method for biologically synthesizing lactose-N-neotetraose by using the beta-1, 4-galactosyl transferase mutant. The invention discloses a protein, which is a protein HpgalT-186 or a protein HpgalT-146-186, a protein HpgalT-146 and a protein HpgalT-146. The protein HpgalT-186 is a protein obtained by mutating an amino acid residue at the 186th site of a wild type HpgalT; the protein HpgalT-146-186 is a protein obtained by carrying out mutation on an amino acid residue at the 186 site and an amino acid residue at the 146 site of wild type HpgalT. On the basis, a series of escherichia coli is constructed and optimized, the yield of the LNnT synthesized through shake flask fermentation of the finally obtained strain reaches 1.73-4.1 g / L, the highest yield in a 5L fermentation tank reaches 20-45.2 g / L, and efficient synthesis of the LNnT is achieved.

The invention relates to the technical field of microorganisms, in particular to application of streptococcus non-lactolyticus GX-7 and a complex microbial inoculant thereof in sugarcane leaf silage, the strain GX-7 is separated from healthy pig manure by a research group, and through detection, the strain has good cholate resistance and is suitable for surviving in intestinal tracts, and the strain GX-7 has good cholate resistance and is suitable for being used as a feed additive. The antibacterial effect on pseudomonas fluorescens, listeria monocytogenes, salmonella choleraesuis and shigella flexneri is achieved; the strain has a good fermentation capability on sugarcane leaves, and the sugarcane leaves are inoculated with a complex microbial inoculant prepared from streptococcus non-lactolyticus GX-7 and streptococcus non-lactolyticus GX-2, so that a synergistic fermentation effect can be achieved; after the silage prepared from the complex microbial inoculant is fed to female buffalo in the gestation period, it is found that the silage can effectively increase the content of milk protein, milk total solids and milk non-fat solids in colostrum of the female buffalo and relieve diarrhea of the female buffalo, and the silage is safe and good.

The invention discloses construction and optimization of a gene editing tool based on CRISPR (clustered regularly interspaced short palindromic repeats)-associated transsposases and application of the gene editing tool in escherichia coli, and belongs to the field of synthetic biology and gene engineering. According to the invention, an efficient gene editing system is established in Escherichia coli, and the burden of a MUSCULAR-CAST system on strains is reduced through element optimization; by eliminating the self-targeting effect, large-fragment (> 10k bp) target gene expression cassettes can be efficiently integrated, and the editing degree of the gene editing system is improved. According to the invention, a MUSCULAR-CAST gene editing system is used for constructing the chassis strains for producing 3-fucosyllactose, L-tryptophan, 2 '-fucosyllactose and neotetraose, so that the chassis strains have equivalent or higher expression yield compared with plasmids, and the growth condition is better or the conversion rate is higher.

The invention belongs to the field of food, and particularly relates to a nutritional composition containing probiotics and breast milk oligosaccharide for improving anxiety or depression and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improving constipation and anxiety state and / or depression state caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a bifidobacterium probiotic, and (ii) a sialylated breast milk oligosaccharide; the bifidobacterium probiotics at least comprise animal bifidobacterium subsp. Lactis, the sialylated breast milk oligosaccharide at least comprises 6 '-sialylated lactose, and the animal bifidobacterium subsp. Lactis comprises a Bb-12 strain. The substance combination of the bifidobacterium probiotics and the sialylated breast milk oligosaccharide can synergistically improve abnormal brain-intestine interaction, and improve constipation and anxiety and / or depression state caused by constipation.

Methods and materials for lipid nanoparticle delivery of nucleic acids are provided herein. For example, compositions containing human milk oligosaccharides in combination with lipid nanoparticles having nucleic acid cargoes are provided herein, as are methods that include administering, to mammals in need thereof, human milk oligosaccharides and lipid nanoparticles that carry nucleic acid cargoes.

The invention provides an application of a transporter in improving the yield and / or purity of lactose-N-neotetraose (LNnT), and relates to the technical field of genetic engineering. Transporter proteins of different sources are screened, the transporter protein which aims at LNnT synthesis and can achieve efficient transportation is obtained, and a new biological material is provided for LNnT synthesis. Moreover, the efficient transporter obtained by screening is used for transporting the LNnT to the outside of cells, so that the pressure on the cells caused by overhigh concentration of intracellular products is relieved, the conversion of an intermediate product LNT II to the LNnT is improved to the maximum extent, the yield is improved while byproducts are reduced, the yield of a byproduct lactose-N-neohexaose is also reduced, and the separation and purification of later products are facilitated.

The present invention provides a combination comprising lactose and human milk oligosaccharides (HMOs) 2'-fucosyllactose (2'-FL), lacto- / V-neotetraose (LNnT), 3- fucosyllactose (3'-FL), at least one of 3'-sialyllactose (3'-SL) or 6'-sialyllactose (6'-SL), and optionally lacto-N-tetraose (LNT) for use in the dietary management of dysbiosis of the gut microbiota in a subject or for use in the dietary management of a disease or disorder associated with metabolism and / or accumulation of BCFA in a subject.

The invention provides a food composition and application thereof in promoting development of intestinal tract glycocalyx layers. The food composition comprises protein, fat, carbohydrate and dietary fiber, and further comprises lactose-N-neotetraose and 3 '-sialic acid lactose, and the ratio of the lactose-N-neotetraose to the 3'-sialic acid lactose is (1: 1)-(3: 1) by weight. In the food composition disclosed by the invention, the lactose-N-neotetraose and the 3 '-sialic acid lactose can be used for up-regulating the transcriptional level of genes, such as has1, has2 and has3, related to the development of the intestinal glycocalyx and the transcriptional level of ext2, so that the development of the intestinal glycocalyx is synergistically promoted.

The invention belongs to the technical field of microbial genetic engineering, and particularly relates to an alpha-2, 3-sialyltransferase mutant and application thereof. The a-2, 3-sialyltransferase mutants V175N, P198A, G173D, D174Q, F196K and A315H are obtained by performing site-specific mutagenesis on six amino acids in an a-2, 3-sialyltransferase amino acid sequence coded by a gene derived from Campylobacter jejuni (OH4384), the yield of 3 '-sialyllactose is remarkably increased by single-point mutagenesis of the V175N, the yield of 3'-sialyllactose is remarkably increased by single-point mutagenesis of the V175N, the yield of 3 '-sialyllactose is remarkably increased by single-point mutagenesis of the P198A, the G173D, the D174Q, the F196K and the A315H, the optimal recombinant microbial strain 3 '-SL-09 (V175N / P198A / D174Q) is obtained through combination of multiple mutation sites, the yield can reach 5.91 g / L, the bottleneck problem of low catalytic efficiency of sialyltransferase is effectively solved, and an enzyme element with excellent performance is provided for high-efficiency and low-cost biological manufacturing of 3'-SL.

The invention discloses a method for enriching whey protein main monomers from cow milk. According to the method, whey protein subjected to membrane separation is taken as a raw material, interaction between main monomers of the whey protein and other milk proteins is weakened by adopting a pH conversion technology and an ultrasonic technology, mineral substances, lactose, bovine serum albumin and residual casein are removed through ion exchange chromatography, the main monomers of the whey protein are enriched, and the high-purity whey protein is obtained. And drying the alpha-lactalbumin and the beta-lactoglobulin to obtain a milk protein product rich in two main monomers of the whey protein, and the total content of the two monomers is up to 85% or above. According to the technology, cow milk serves as a raw material, efficient enrichment of two main monomers of whey protein can be achieved only through membrane separation, pH conversion, ultrasonic assistance and ion exchange chromatography, only pH needs to be adjusted in the separation process, other chemical reagents are not added, and the process is environmentally friendly, simple, easy to implement and suitable for large-scale processing; the prepared milk protein base material rich in the whey protein main monomer can be used as a main material and a base material of infant food, and is high in nutritional value and wide in application prospect.

The invention belongs to the field of nutrient substance research, and particularly relates to application of a nutrient composition to regulation of brain immunity. The invention provides application of a nutritional composition in preparation of food for regulating brain immunity. Wherein the nutritional composition comprises the following necessary components: lactoferrin and fucosyllactose, and in the nutritional composition, the mass ratio of the lactoferrin to the fucosyllactose is 1: (0.1-30). Research finds that after lactoferrin and fucosyllactose are combined according to a certain proportion, the lactoferrin and fucosyllactose have a synergistic effect of regulating brain immunity. Experimental data show that after the combination of lactoferrin and fucosyllactose is used for treating the BV2 cells, the trend that the BV2 cells are differentiated into M2 phenotype microglial cells is higher than the trend that the BV2 cells are differentiated into M1 phenotype microglial cells, and the amount of secreted inflammatory factors is obviously reduced.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The present invention relates to a combination of a mixture of galactooligosaccharides (GOS) and human milk oligosaccharides (HMO), or a nutritional composition comprising such a combination. The combination or composition is useful for the treatment and / or prevention of stress and / or mood disorders in infants, toddlers and / or children. The mixture of HMO consists of or consists essentially of 2 '-fucosyllactose (2' FL) and difucosyllactose (DFL) or lactose-N-tetrasaccharide (LNT) and 6 '-sialyllactose (6' SL). The invention also relates to the use of a combination of a mixture of galactooligosaccharides (GOS) and human milk oligosaccharides (HMO) or a composition comprising such a combination for the treatment and / or prevention of stress and / or mood disorders in infants, toddlers and / or children, wherein the mixture of HMO consists of or consists essentially of 2 '-fucosyllactose (2' FL) and difucosyllactose (DFL) or lactose-N-tetrasaccharide (LNT) and 6 '-sialyllactose (6' SL).

To provide a packaged acidic heat-treated beverage preparation which contains whey protein and has an improved organoleptic property and / or visual property.SOLUTION: A packaged heat-treated preparation includes the following: a) proteins in a total amount of 2 to 45% w / w based on a weight of a beverage, whose at least 85% w / w is β-lactoglobulin (BLG); and optionally b) a sweetener, a sugar polymer, and / or an aroma material, the preparation having a pH in a range of 2 to 4.7.SELECTED DRAWING: None

The invention provides a method for preparing lactulose from immobilized beta-galactosidase, and belongs to the technical field of functional sugar preparation.The method comprises the following steps that an immobilized enzyme column is prepared, specifically, macroporous alkalescent styrene anion exchange resin is soaked and washed with an ethanol solution, a NaCl solution, an HCl solution and a NaOH solution in sequence; the pretreated resin and beta-galactosidase liquid are mixed, a buffer solution is added, shaking table adsorption is performed, and standing is performed after adsorption; adding a glutaraldehyde solution for cross-linking, and discarding the supernatant to obtain an immobilized enzyme column; adding a magnesium ion solution into a mixed solution of lactose and fructose, and then performing conversion through an immobilized enzyme column to obtain a lactulose conversion solution; the lactulose conversion liquid is sequentially subjected to decoloration, ion exchange, vacuum concentration and continuous simulated moving bed chromatographic separation to obtain a lactulose solution, by means of the method, the lactulose conversion rate is larger than or equal to 60%, the lactulose yield is larger than or equal to 92%, the preparation process is simple, and the cost is low.

The invention provides cream cheese and a preparation method thereof, and belongs to the technical field of dairy product processing. According to the method, firstly, raw milk is subjected to degreasing and membrane filtration concentration, the concentration multiple is controlled to be 1.5-4, the lactose content of the concentrated solution is precisely regulated and controlled to be 3-6.5% through washing filtration, and the raw milk concentrated solution rich in casein (accounting for 85-95% of total protein) is obtained. Then, mixing the concentrated solution with single cream, white granulated sugar and the like, homogenizing, sterilizing, inoculating a leavening agent and chymosin, fermenting, refrigerating and demulsifying to obtain a finished product. According to the invention, nutrition waste and environmental pollution caused by discharge of whey in a traditional process are fundamentally avoided through membrane filtration pretreatment, and meanwhile, the problems of pink feeling and peculiar smell caused by addition of milk protein powder are solved; the obtained product is pure and rich in flavor, fine and smooth in texture, simple and efficient in process and suitable for large-scale production.

The invention discloses a bacillus coagulans feed additive and a preparation method thereof, and relates to the technical field of feed additives, the bacillus coagulans feed additive comprises bacillus coagulans spores, the content of the spores is 1.0 * 10 < 8 >-1.0 * 10 < 11 > CFU / g; the protective agent system comprises the following components: maltodextrin or lactose, vegetable protein, polyhydric alcohol and an antioxidant; the invention discloses a microcapsule coating structure. A microcapsule is a two-layer composite coating of an inner layer alginate matrix and an outer layer polycation or polymer coating. According to the invention, bacillus coagulans spores which can still keep high survival rate under short-time high-temperature and low-pH conditions are obtained through screening and fermentation strategies of strains with high sporulation and heat and acid tolerance, the problem that common strains are easy to inactivate in granulation, extrusion and gastric acid environments is solved, the problem of product failure caused by insufficient tolerance of the strains is reduced, and the product quality is improved. And the original biological activity basis is improved, so that the protection effect of the subsequent formula and the coating can be played at a higher starting point, and the zoology effect of the final preparation is improved.

The invention discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. According to the invention, the 1, 3-dioleic acid-2-palmitin, the osteopontin and the oligosaccharide are compounded for use, and the components interact to promote mutual absorption and utilization, so that the growth and development of bones in the growth period of infants are improved, the mineral content and the bone mineral density of the bones are increased, the health of the bones is promoted, and the composition is safe and free of side effects. And by optimizing the variety of the oligosaccharide, the compound use of the galactooligosaccharide and the 2 '-fucosyllactose is found to be capable of better improving the growth and development of bones in the growth period of the infants.

The invention belongs to the technical field of nutritious food, and discloses a composition for simulating whole breast milk oligosaccharide and application of the composition. In the composition for simulating the whole breast milk oligosaccharide, the mass ratio of 2 '-fucosyllactose to lactose-N-neotetraose to 3'-sialyllactose is (3.9-8.1): (0.8-1.2): (0.8-1.2), and the breast milk oligosaccharide 2 '-fucosyllactose, the lactose-N-neotetraose and the 3'-sialyllactose are mutually matched to take effect in a synergistic manner, so that the whole breast milk oligosaccharide is obtained. The composition can improve the memory ability and cognitive ability of an eating object, can be added into infant food (including infant formula powder, complementary food and nutritional supplements) and nutritional supplements or food of children over 3 years old, teenagers and aged people, and has a wide application prospect.

The invention provides an engineering bacterium for producing 3 '-sialyllactose as well as a construction method and application thereof. The engineering bacterium has the capability of generating 3 '-sialic acid lactose, and an exogenous UDP-N-acetyl glucosamine-2-epimerase gene (neuC), a sialic acid synthase gene (neuB), an N-acetylneuraminic acid cytidyltransferase gene (css) and an alpha-2, 3-sialic acid transferase gene (ST) are introduced into a genome of the engineering bacterium or a recombinant plasmid carried by the engineering bacterium. The engineering bacterium has high capacity of producing 3 '-sialyllactose under the condition that antibiotics are not needed.

The invention belongs to the technical field of food, and relates to application of breast milk oligosaccharide in regulating brain immunity. Specifically, the invention relates to the non-therapeutic purpose of adjusting brain immunity by adjusting polarization of microglial cells M1 / M2, and the breast milk oligosaccharide is any one of 3-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3 '-sialic acid lactose and 6'-sialic acid lactose. Research results show that a specific variety of breast milk oligosaccharides (especially 3-FL) can obviously inhibit the generation of neurotoxic factors NO, inflammatory factors TNF-alpha and IL-1beta in microglial cells, and promote the generation of anti-inflammatory cytokines IL-10 in the microglial cells, so that the state of the microglial cells is improved, damage repair is promoted, and the microglial cells are prevented from being damaged. Therefore, the effect of regulating brain immunity is achieved.